AnaptysBio Announces Pricing of Public Offering of Common Stock
September 25, 2018 19:49 ET
|
AnaptysBio, Inc.
SAN DIEGO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ: ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
AnaptysBio Announces Proposed Public Offering of Common Stock
September 24, 2018 16:01 ET
|
AnaptysBio, Inc.
SAN DIEGO, Sept. 24, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ: ANAB), a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
AnaptysBio Reports Positive Topline Data from Phase 2a Proof-of-Concept Clinical Trial of Etokimab in Severe Eosinophilic Asthma
September 24, 2018 06:30 ET
|
AnaptysBio, Inc.
Lung function improvement occurred rapidly following a single dose of etokimab, with an 8 percent increase in FEV1 over placebo at Day 2FEV1 improvement was sustained throughout the interim analysis...
AnaptysBio Announces Second Quarter 2018 Financial Results and Provides Pipeline Updates
August 07, 2018 06:30 ET
|
AnaptysBio, Inc.
Top-line Phase 2a Data from Etokimab (ANB020) in Eosinophilic Asthma Expected in Third Quarter of 2018Etokimab Clinical Development Program Expanded to Include Chronic Rhinosinusitis with Nasal...
AnaptysBio to Present at the 2018 Wedbush PacGrow Healthcare Conference
August 06, 2018 06:30 ET
|
AnaptysBio, Inc.
SAN DIEGO, Aug. 06, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
AnaptysBio to Present at the Jefferies 2018 Global Healthcare Conference
May 30, 2018 06:30 ET
|
AnaptysBio, Inc.
SAN DIEGO, May 30, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
AnaptysBio Presents Updated ANB020 and ANB019 Clinical Data at the 2018 EAACI Congress
May 29, 2018 08:30 ET
|
AnaptysBio, Inc.
Blood eosinophil level reduction consistent with clinical efficacy in ANB020 Phase 2a atopic dermatitis trialANB020-mediated eosinophil reduction is aligned with genotypic data from prior human IL-33...
AnaptysBio Announces First Quarter 2018 Financial Results and Provides Pipeline Updates
May 08, 2018 16:15 ET
|
AnaptysBio, Inc.
Positive Phase 2a Proof-of-Concept Data Reported from ANB020 Trials in Atopic Dermatitisand Peanut Allergy Top-Line Phase 2a Data from ANB020 in Eosinophilic Asthma Expected in the Third Quarter of...
AnaptysBio Announces ANB020 and ANB019 Clinical Data Presentations at the 2018 EAACI Congress
May 01, 2018 06:30 ET
|
AnaptysBio, Inc.
SAN DIEGO, May 01, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...
AnaptysBio To Participate in Upcoming Investor Conferences
April 27, 2018 06:30 ET
|
AnaptysBio, Inc.
SAN DIEGO, April 27, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical...